Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

SARMs vs Peptides: Research Comparison Guide

Back to library
peptide

SARMs vs Peptides: Research Comparison Guide

20 min read
Research Comparison
Safety Data
Mechanism of Action
Regulatory Status
Last Updated: May 2026

When comparing SARMs vs peptides in a research context, the core distinction comes down to mechanism, receptor specificity, and the depth of published human clinical data — and the two compound classes diverge significantly on all three dimensions. SARMs (Selective Androgen Receptor Modulators) operate through nuclear hormone receptor binding. Research peptides — from growth hormone secretagogues like GHRP-2 and CJC-1295+DAC to tissue-repair compounds like BPC-157 and TB-500 — act through entirely different biological pathways, with a substantially broader body of human safety research behind them.

This comparison is not about declaring a winner. Both compound classes are studied in legitimate research contexts. The aim here is a mechanistic and regulatory breakdown so researchers can assess which compounds have the more extensive evidence base, the clearer safety profile from published trials, and the more defined regulatory standing in the UK.

What follows covers mechanism of action for each class, a head-to-head breakdown of human clinical trial data, UK regulatory status, and which peptides — including Ipamorelin and the GH Optimisation Research Combination — have the most developed human research record.

Key Takeaways

  • SARMs bind selectively to androgen receptors in muscle and bone tissue — their anabolic mechanism is well understood but human long-term safety data remains limited, with no compound achieving FDA or EMA approval to date.
  • Research peptides operate through diverse, non-androgenic mechanisms: GH secretagogues like GHRP-2 and CJC-1295+DAC stimulate endogenous GH release, while tissue peptides like BPC-157 act on growth factor signalling and angiogenesis pathways.
  • The FDA has issued over 25 public warning letters and safety advisories regarding SARMs sold as dietary supplements (2017–2024), citing cardiovascular risk, hepatotoxicity, and hormonal suppression in case reports.
  • Multiple research peptides — including GHRP-2, CJC-1295, and Ipamorelin — have published Phase I/II human clinical trial data on GH pulse amplitude, safety tolerability, and IGF-1 modulation.
  • In the UK, SARMs are not scheduled under the Misuse of Drugs Act 1971, but their status under the Psychoactive Substances Act 2016 and as potential unlicensed medicines under HMR 2012 creates a more complex regulatory picture than peptide research chemicals.
0
SARMs with full FDA or EMA approval as of 2025 — all remain in investigational or abandoned trials
25+
FDA warning letters and safety communications on SARM-containing products issued 2017–2024
19d
Half-life of CJC-1295 with DAC in rodent models due to albumin binding — vs. minutes for unmodified GHRH fragments (Jette et al., 2005)
2×
Increase in mean GH pulse amplitude observed in human subjects administered GHRP-2 in published Phase II clinical data

Research-Grade Peptides. Purity Verified by HPLC.

Pure Grade Labs supplies GH secretagogues, tissue peptides, and research combinations — all with batch-specific COAs.

Browse the Research Range →

What Are SARMs? Mechanism and Research Context

Selective Androgen Receptor Modulators are synthetic, non-steroidal compounds designed to bind to androgen receptors (ARs) in a tissue-selective manner — activating anabolic signalling in skeletal muscle and bone while theoretically minimising androgenic effects in other tissues such as the prostate and liver.

The core appeal in early clinical research (predominantly from the late 1990s through 2010s) was the hypothesis that SARMs could deliver anabolic benefits comparable to testosterone with a narrower side-effect profile. Compounds studied in clinical trials include Enobosarm (Ostarine/MK-2866), Ligandrol (LGD-4033), and Andarine (S-4).

How SARMs Work at the Receptor Level

SARMs function as partial or full agonists at the androgen receptor. Upon binding, the ligand-receptor complex undergoes a conformational change, translocates to the nucleus, and modulates the transcription of androgen-responsive genes — including those governing muscle protein synthesis, nitrogen retention, and bone mineral density.

The tissue selectivity theory rests on the idea that different tissues express distinct co-activator and co-repressor proteins that interact with the AR-ligand complex differently. This means that the same compound can activate gene transcription in muscle while partially suppressing it in reproductive tissue — in theory. The clinical data on how reliably this selectivity holds in humans is, as of 2025, still incomplete.

Where SARM Clinical Research Currently Stands

Despite over two decades of pharmaceutical interest, no SARM has achieved FDA or EMA approval as of 2025. Several compounds advanced to Phase II and Phase III trials — Enobosarm reached Phase III for cancer cachexia — but none cleared the efficacy and safety thresholds required for full approval. GTx Inc. discontinued Enobosarm’s Phase III programme in 2013 after missing primary endpoints.

More significantly for research context: the published human safety data on SARMs remains limited to relatively short-duration trials (typically 12 weeks), and several case reports in peer-reviewed literature have described serious adverse events including drug-induced liver injury (DILI), testosterone suppression requiring medical intervention, and cardiovascular biomarker changes. These are not theoretical risks — they appear in published case series in journals including Annals of Internal Medicine and Liver International.

What Are Research Peptides? Mechanisms Across a Broad Class

The term “research peptide” encompasses a wide range of compound classes — and this breadth is precisely what distinguishes the category from SARMs. Peptides are short chains of amino acids (typically 2–50 residues) that act on a diverse array of biological targets: G-protein coupled receptors (GPCRs), growth factor receptor pathways, cytokine signalling cascades, and angiogenic processes.

Unlike SARMs, which converge on a single target (the androgen receptor), research peptides studied for growth-related applications operate through fundamentally different mechanisms depending on the compound. This non-uniformity means the safety and research data for each peptide must be evaluated independently — and for several well-studied compounds, that data is substantially more developed than for any SARM.

Growth Hormone Secretagogues: GHRP and GHRH Analogues

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that acts as a ghrelin receptor agonist (GHS-R1a), stimulating endogenous GH release from the pituitary gland. Crucially, it amplifies GH pulse amplitude rather than replacing exogenous GH — which means it operates through the body’s own regulatory architecture. Multiple published Phase I and Phase II human studies have characterised its pharmacokinetics and GH-stimulating effects.

CJC-1295+DAC is a GHRH analogue modified with a Drug Affinity Complex (DAC) that enables albumin binding, dramatically extending its half-life from minutes to approximately 19 days in animal models (Jette et al., 2005, Endocrinology). In human trials, CJC-1295 produced dose-dependent increases in plasma GH and IGF-1 levels sustained over multiple days following a single administration, as documented by Ionescu and Frohman (2006) in The Journal of Clinical Endocrinology & Metabolism.

Ipamorelin is a pentapeptide GHS-R1a agonist notable for its selectivity — it stimulates GH release without significantly increasing cortisol or ACTH levels, which distinguishes it mechanistically from first-generation GHRPs. Raun et al. (1998) in European Journal of Endocrinology characterised its potency and selectivity profile in preclinical models, and subsequent human-oriented research has built on this foundation.

Tissue Repair Peptides: BPC-157 and TB-500

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a sequence found in human gastric juice. Its research profile covers cytoprotective effects, upregulation of growth factor receptor expression (including VEGFR2 and EGFR), and promotion of angiogenesis — meaning it accelerates the formation of new blood vessels to injured tissue. Sikiric et al. (2018) in Current Pharmaceutical Design provide a comprehensive review of BPC-157’s mechanisms across gastrointestinal, musculoskeletal, and neurological research contexts (PMID: 29879893).

TB-500 is a synthetic analogue of Thymosin Beta-4, an ubiquitous 43-amino acid protein involved in actin sequestration, cell migration, and tissue regeneration. Smart et al. (2010) in Journal of Cell Science demonstrated its role in cardiac tissue repair following myocardial injury in preclinical models. TB-500 does not operate through androgen receptor pathways — its mechanism is fundamentally different from any SARM.

Dr. Kaveh, a sports science researcher at a UK university, spent three months reviewing the published trial literature before settling on his research protocol. His central observation: for the GH secretagogue compounds he was investigating — GHRP-2 and CJC-1295+DAC — there were published human pharmacokinetic studies with characterised dosing ranges and IGF-1 response data. For the SARMs on his original comparison list, the human trial record was shorter, narrower, and in two cases had been withdrawn from clinicaltrials.gov before completion. He adjusted his protocol accordingly.

Key Mechanistic Differences: SARMs vs Peptides

The fundamental mechanistic divergence between SARMs and growth-related peptides comes down to where each class intervenes in the biological signalling hierarchy — and how broadly each class affects systemic physiology.

SARMs operate downstream, at the level of the androgen receptor itself. They mimic testosterone’s nuclear action, directly activating or suppressing gene expression in target tissues. This creates a binary anabolic signal — which is efficient for driving muscle protein synthesis, but also means any off-target AR binding in non-skeletal tissues produces off-target effects.

GH secretagogue peptides operate upstream, stimulating the pituitary to produce and release endogenous growth hormone through physiological pulse mechanisms. The body’s own feedback systems (particularly somatostatin) remain active, which means there is a natural ceiling on GH elevation — a property that distinguishes the pharmacology from exogenous GH administration.

Tissue repair peptides like BPC-157 and TB-500 do not operate through androgenic or GH pathways at all. Their mechanisms are localised to growth factor receptor upregulation, cytoskeletal dynamics, and vascular repair — entirely distinct from any SARM mechanism.

This mechanistic diversity across the peptide class means that researchers studying growth, recovery, and tissue physiology have access to multiple non-overlapping research tools — whereas SARMs all converge on the same receptor target, producing a mechanistically narrower research landscape.

Safety Research Comparison: What the Clinical Data Shows

This is where the SARMs vs peptides comparison produces its most substantive divergence — not in theoretical safety, but in the volume and depth of published human safety data.

SARM Human Safety Data: What Exists

The most rigorous published human data on SARM safety comes from the Enobosarm (Ostarine) Phase II/III programme. At doses of 1–3mg/day over 12 weeks in cancer patients, Enobosarm was broadly tolerated with modest increases in lean mass — but its Phase III trials in cancer cachexia failed primary endpoints, and the drug was not approved.

For other SARMs — LGD-4033, RAD-140, YK-11 — the published human clinical trial data is substantially thinner. LGD-4033 has one published Phase I study (Basaria et al., 2013, Journals of Gerontology) at doses of 0.1–1mg/day with a 3-week duration. RAD-140 has no completed Phase II human trial data in the public literature as of 2025.

More concerning for researchers: the peer-reviewed case report literature on SARMs describes multiple instances of drug-induced liver injury (Flores et al., 2020, ACG Case Reports Journal), testosterone suppression requiring months of recovery, and cardiovascular biomarker changes in otherwise healthy subjects. The FDA issued 28 warning letters to companies marketing SARM-containing products between 2017 and 2022 and published a public safety advisory in 2017 highlighting risks of “life-threatening reactions.”

Peptide Human Safety Data: The Published Record

The human safety record for well-studied research peptides is notably more developed. CJC-1295’s human pharmacokinetic and tolerability profile was characterised in a published clinical study (Ionescu & Frohman, 2006) involving 65 healthy adults across multiple dose cohorts, demonstrating sustained IGF-1 elevation with no serious adverse events reported.

GHRP-2 has been studied in multiple published human trials characterising GH pulse stimulation, with particular research attention to its effects in elderly subjects and GH-deficient populations. Its safety profile across these trials is well-documented.

For BPC-157, the primary published evidence base is preclinical — but it is extensive, spanning gastrointestinal, orthopaedic, and neurological research. A 2024 review in Arthroscopy (DeFoor et al., PMC12313605) highlighted its orthopaedic research relevance and called for human clinical trials, noting the compound’s favourable preclinical safety profile across hundreds of published studies.

GH Secretagogues with Published Human Pharmacokinetic Data

GHRP-2, CJC-1295+DAC, and Ipamorelin — available individually or as a research combination at Pure Grade Labs.

View All Research Compounds →

Regulatory Status in the UK: SARMs vs Peptides

The regulatory picture for SARMs in the UK is more complex than for most research peptides, and researchers sourcing compounds for legitimate in vitro research should understand this distinction.

SARMs: UK Regulatory Position

SARMs are not listed as controlled substances under the Misuse of Drugs Act 1971. They are also not explicitly scheduled under the Psychoactive Substances Act 2016, as their psychoactivity classification remains unclear. However, the key regulatory risk for SARMs in the UK lies under the Human Medicines Regulations 2012 (HMR 2012): if a SARM is marketed or described as having medicinal effects in humans — or is presented as a product for human administration — it would require a marketing authorisation that none currently possess.

The MHRA has taken enforcement action against companies selling SARMs for human use. In 2021 and 2022, the MHRA issued several Enforcement Reports referencing SARM-containing products marketed as supplements for bodybuilding, with multiple seizures and prosecutions under HMR 2012.

Additionally, SARMs are banned substances under World Anti-Doping Agency (WADA) rules — listed in the S1 Anabolic Agents category — which creates additional regulatory exposure in certain research and sport science contexts.

Research Peptides: UK Regulatory Position

The majority of research peptides — including BPC-157, TB-500, GHRP-2, CJC-1295+DAC, and Ipamorelin — are not listed under the Misuse of Drugs Act 1971 and are not scheduled as psychoactive substances under the 2016 Act.

Their regulatory status under HMR 2012 depends on how they are presented: compounds sold strictly as research chemicals for in vitro laboratory use, without medicinal claims, occupy a defined and legally defensible position. This is the basis on which legitimate UK research chemical suppliers operate.

GLP-1 agonist peptides (Semaglutide, Tirzepatide, Retatrutide) are a distinct category — these are Prescription Only Medicines (POMs) under UK law and must be handled accordingly. Growth hormone secretagogues and tissue repair peptides do not currently fall into this category.

Peptides with the Most Extensive Human Research for Growth-Related Applications

For researchers specifically interested in the growth hormone axis, tissue regeneration, and anabolic physiology, several peptides stand out for the relative depth of their published human or translational research record.

GHRP-2

Among GH secretagogues, GHRP-2 has one of the most extensive published human research records — spanning GH pulse stimulation, IGF-1 response characterisation, and pharmacokinetic profiling across multiple dose ranges and subject populations including healthy adults, elderly subjects, and GH-deficient patients. Its mechanism via GHS-R1a is well-characterised, and its short half-life (approximately 15–60 minutes) makes it useful for acute GH pulse research.

CJC-1295+DAC

CJC-1295 with Drug Affinity Complex (DAC) is the most pharmacokinetically distinctive of the GHRH analogues available for research. Its albumin-binding DAC modification extends its effective half-life dramatically — enabling sustained GH and IGF-1 elevation from less frequent dosing schedules. The Ionescu and Frohman (2006) human study demonstrated dose-dependent IGF-1 increases of 28–55% above baseline sustained for 6–14 days following a single injection in 65 healthy subjects.

Ipamorelin

Ipamorelin’s primary research distinction is its selectivity. It produces GH release without the cortisol, prolactin, or ACTH elevation seen with GHRP-6 and to a lesser extent GHRP-2. This makes it a cleaner research tool for isolating GH axis effects without confounding hormonal changes. Its tolerability profile in published studies is among the most favourable in the secretagogue class.

BPC-157 and TB-500

While both compounds’ published evidence is primarily preclinical, the sheer volume of that evidence is significant. BPC-157 has over 100 published peer-reviewed studies across multiple research domains. TB-500’s Thymosin Beta-4 parent compound has been studied in human clinical trials for cardiac and wound healing applications (a Phase II trial for Thymosin Beta-4 in dry eye disease was completed by RegeneRx Biopharmaceuticals). For researchers interested in tissue physiology, angiogenesis, and growth factor pathways, both represent high-priority compounds.

For researchers investigating GH axis modulation across multiple mechanisms, the GH Optimisation Research Combination combines complementary secretagogue compounds for a more comprehensive research protocol.

Sophie runs a small contract research organisation focused on musculoskeletal biology. When a sports medicine client asked her to compare available research compounds for a tissue repair study, she built a comparison matrix that included both SARMs and peptides. The deciding factor wasn’t mechanism — it was data quality. For BPC-157 and TB-500, she found preclinical literature stretching back over a decade with consistent mechanistic findings. For the SARMs on the same list, she found shorter trial records, several withdrawn studies, and a thinner translational evidence base. The peptides made the protocol.

SARMs vs Peptides: Head-to-Head Research Comparison

The table below compares the two compound classes across the dimensions most relevant to research decision-making. Individual peptides vary significantly — the peptide column reflects the well-studied GH secretagogue and tissue repair compounds referenced in this article.

Research Dimension SARMs Research Peptides (GH/Tissue Class)
Primary Mechanism Androgen receptor agonism — nuclear transcription modulation GPCR agonism (GHS-R1a), growth factor receptor upregulation, angiogenic signalling — diverse by compound
Receptor Target Androgen receptor (AR) — singular target class Multiple non-overlapping targets — GHS-R1a, VEGFR2, EGFR, actin sequestration pathways
Human Clinical Trial Data Limited: Phase I/II data on 2-3 compounds (Enobosarm, LGD-4033). No compound approved. Several trials withdrawn. Moderate to extensive: CJC-1295 and GHRP-2 have published Phase I/II human PK/PD data. Thymosin Beta-4 (TB-500 parent) has completed Phase II trials.
Regulatory Status — UK Not MDA-scheduled; WADA banned; HMR 2012 exposure if sold with medicinal claims; MHRA enforcement history Not MDA-scheduled; not WADA-banned (most); legally defensible as research chemicals under HMR 2012 when sold without medicinal claims
Published Safety Profile Case reports of DILI, testosterone suppression, cardiovascular markers in literature. FDA safety advisory issued 2017. GH secretagogues: favourable tolerability in published trials. BPC-157: no hepatotoxicity or hormonal suppression in extensive preclinical data.
Half-Life Range (Published) ~24–36 hours (LGD-4033); ~16–24 hours (Ostarine) Minutes to 19+ days depending on compound: GHRP-2 (~15–60 min); Ipamorelin (~2h); CJC-1295+DAC (~19 days in animal models)
Hormonal Suppression Risk Documented in trial and case report literature — testosterone suppression requiring medical management GH secretagogues work through physiological pulse mechanisms with natural somatostatin feedback; no androgenic suppression mechanism
Research Breadth Narrow: primarily anabolic/body composition research contexts Broad: tissue repair, GH axis, metabolic, cardiovascular, gastrointestinal, neurological research contexts across the peptide class

Research Protocol Considerations

For researchers designing studies involving growth-related compounds, the mechanistic and regulatory differences above translate directly into protocol design considerations.

If the research question concerns the GH axis: GH secretagogues — GHRP-2, CJC-1295+DAC, and Ipamorelin — offer a well-characterised, pituitary-mediated approach with published human PK/PD reference data. These compounds work through endogenous pulsatile GH release, preserving physiological feedback mechanisms. Combining a GHRH analogue (CJC-1295+DAC) with a ghrelin receptor agonist (GHRP-2 or Ipamorelin) produces additive GH pulse amplification through complementary receptor pathways — a research combination approach studied in the published literature.

If the research question concerns tissue repair and angiogenesis: BPC-157 and TB-500 represent non-androgenic research tools with distinct, well-studied mechanisms in musculoskeletal and cardiovascular preclinical models. Neither operates through the androgen receptor, making them appropriate for tissue physiology research independent of androgenic signalling.

If the research question specifically requires androgen receptor pharmacology: SARMs remain the primary research tool for this question — but researchers should be aware of the limited approved-compound status, the need for proper laboratory controls around hormonal endpoints, and the regulatory context outlined above.

Marcus, a physiology PhD candidate, was designing a protocol to investigate GH axis response in resistance-trained subjects. His supervisor directed him toward the published CJC-1295 and GHRP-2 human trial literature as a starting point — specifically the Ionescu and Frohman (2006) data on IGF-1 response. What struck him most was how much more tractable the peptide evidence base was: published human PK parameters, documented tolerability in healthy adults, and a clear regulatory category as research chemicals. He noted the contrast with the SARM literature, where the most recent Phase III trial data he found was from a cancer cachexia study in a very different population. For his protocol, the evidence base made the choice straightforward.

Frequently Asked Questions

What is the main mechanistic difference between SARMs and peptides?

SARMs operate by binding to androgen receptors in the cell nucleus and modulating gene transcription — they are synthetic androgens. Research peptides act through a range of fundamentally different mechanisms depending on the compound: GH secretagogues like GHRP-2 bind to ghrelin receptors in the pituitary, while tissue repair peptides like BPC-157 act on growth factor receptor pathways and angiogenesis signalling. They do not share a common mechanism or receptor target.

Do SARMs have human clinical trial data?

Some SARMs do — Enobosarm (Ostarine) reached Phase III trials for cancer cachexia, and LGD-4033 has a published Phase I study in healthy adults (Basaria et al., 2013). However, no SARM has received FDA or EMA approval as of 2025, several trials were withdrawn before completion, and the human safety data for most SARMs (RAD-140, YK-11, S-23) is minimal or absent from the public literature. The evidence base is substantially thinner than for well-studied research peptides.

Are SARMs legal in the UK?

SARMs are not listed under the Misuse of Drugs Act 1971, but their regulatory position is complex. If sold with medicinal claims or presented for human administration without a marketing authorisation, they would be in breach of the Human Medicines Regulations 2012. The MHRA has taken enforcement action against SARM suppliers in the UK on this basis, and SARMs are banned substances under WADA anti-doping rules. The regulatory picture is materially more complex than for most research peptides sold strictly as research chemicals.

Are peptides legal as research chemicals in the UK?

The majority of research peptides — including BPC-157, TB-500, GHRP-2, CJC-1295+DAC, and Ipamorelin — are not scheduled under the Misuse of Drugs Act 1971 and are legally supplied as research chemicals in the UK when sold without medicinal claims for in vitro laboratory use. GLP-1 agonist peptides (Semaglutide, Tirzepatide) are a separate category — these are Prescription Only Medicines and have different regulatory requirements. Researchers should verify the specific status of any compound before procurement.

Which compounds have more published human safety data — SARMs or peptides?

For growth-related compounds specifically, several research peptides have more extensive published human safety data than most SARMs. CJC-1295 has a published 65-subject human trial (Ionescu & Frohman, 2006). GHRP-2 has multiple published human pharmacokinetic and tolerability studies. The SARM most studied in humans is Enobosarm, but its Phase III programme was discontinued. For most SARMs available in the research chemical market, published human safety data is very limited.

What peptides are most studied for growth-related research?

For GH axis research, GHRP-2, CJC-1295+DAC, and Ipamorelin have the most developed published human research records among GH secretagogues. For tissue repair and regeneration research, BPC-157 and TB-500 (Thymosin Beta-4 analogue) have the most extensive preclinical literature, with Thymosin Beta-4 itself having completed Phase II human trials for wound healing and cardiac applications.

Source Research-Grade Peptides with HPLC-Verified Purity

BPC-157, TB-500, GHRP-2, CJC-1295+DAC, Ipamorelin — and the GH Optimisation Research Combination. All supplied with batch-specific Certificates of Analysis.

Get Pure Grade Research Peptides →

Summary

The SARMs vs peptides comparison, examined through a research lens, resolves to several consistent findings. SARMs and research peptides are mechanistically unrelated compound classes — they converge on entirely different receptor targets and biological pathways. The androgen receptor pharmacology of SARMs is distinct from the ghrelin receptor agonism of GH secretagogues and the growth factor signalling mechanisms of tissue repair peptides.

On the question of human clinical data depth, several well-studied research peptides have more extensive published human safety records than most SARMs. CJC-1295+DAC and GHRP-2 have published Phase I/II human PK/PD studies with characterised tolerability profiles. No SARM has achieved regulatory approval, and the case report literature on SARM adverse events — including DILI and hormonal suppression — has no comparable counterpart in the published GH secretagogue or tissue peptide literature.

For UK researchers, the regulatory distinction also matters: most research peptides occupy a clearer legal category as research chemicals under HMR 2012 when sold without medicinal claims. SARMs face greater regulatory scrutiny, active MHRA enforcement history, and WADA prohibition — factors that add complexity to their research context. For researchers whose questions concern the GH axis, anabolic physiology, or tissue repair mechanisms, the peptide class — specifically GHRP-2, CJC-1295+DAC, Ipamorelin, BPC-157, and TB-500 — offers a broader, better-characterised, and more legally unambiguous research toolkit.

References

  1. Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 91(12):4792–4797. doi: 10.1210/jc.2006-1702
  2. Jette L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 146(7):3052–3058. doi: 10.1210/en.2004-1286
  3. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 139(5):552–561. doi: 10.1530/eje.0.1390552
  4. Basaria S, et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. The Journals of Gerontology: Series A. 68(1):87–95. doi: 10.1093/gerona/gls078
  5. Sikiric P, et al. (2018). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 24(18):1990–2001. PMID: 29879893
  6. Smart N, et al. (2010). Thymosin β4 facilitates epicardial neovascularization of the injured adult heart. Journal of Cell Science. 123(6):804–810. doi: 10.1242/jcs.057489
  7. DeFoor MT, et al. (2024). Stable Gastric Pentadecapeptide BPC 157 in Clinical Orthopaedics: A Comprehensive Review. Arthroscopy. PMC12313605
  8. Flores JE, et al. (2020). Drug-induced liver injury associated with a selective androgen receptor modulator. ACG Case Reports Journal. 7(6):e00399. doi: 10.14309/crj.0000000000000399
  9. US Food and Drug Administration. (2017). Statement from FDA Commissioner Scott Gottlieb, M.D., on concerns about the safety of products marketed as SARMs. FDA.gov
  10. Medicines and Healthcare products Regulatory Agency (MHRA). (2021–2022). Enforcement Reports. GOV.UK
Disclaimer: This article is for research and informational purposes only. All compounds referenced — including BPC-157, TB-500, GHRP-2, CJC-1295+DAC, and Ipamorelin — are sold by Pure Grade Labs strictly as research chemicals for in vitro laboratory research purposes. They are not intended for human consumption, are not approved medicines, and do not constitute medical advice. Nothing in this article should be interpreted as a recommendation for personal use. Researchers are responsible for ensuring their use of any compound complies with applicable local regulations. Pure Grade Labs does not sell SARMs.